Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nexalin Technology, Inc. - Common Stock (NQ: NXL ) 1.240 +0.070 (+5.98%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Nexalin Technology, Inc. - Common Stock < Previous 1 2 Next > Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV July 26, 2024 Via ACCESSWIRE Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery July 18, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Closing of $5.2 Million Public Offering July 01, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Pricing of $5.2 Million Public Offering June 27, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia June 20, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV June 14, 2024 Via ACCESSWIRE Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) June 13, 2024 Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders From Nexalin Technology, Inc. Via GlobeNewswire MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies June 06, 2024 Via ACCESSWIRE Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th June 04, 2024 From Nexalin Technology, Inc. Via GlobeNewswire FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device June 03, 2024 Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts May 22, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23 May 09, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements April 25, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing April 09, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device April 04, 2024 New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board April 02, 2024 Previously served as Acting General Counsel to the Department of Veterans Affairs From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego March 28, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology March 14, 2024 Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” March 13, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia March 06, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device February 08, 2024 Company’s International Reach Expanding with Latest Regulatory Approval From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System January 23, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Unveils Next-Generation HALO™ Clarity January 11, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression December 18, 2023 Results published in General Psychiatry, a leading peer-reviewed journal From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter October 25, 2023 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures October 16, 2023 Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and... From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms August 07, 2023 New migraine data builds on prior clinical studies in depression From Nexalin Technology, Inc. Via GlobeNewswire Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time August 03, 2023 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies July 26, 2023 From Nexalin Technology, Inc. Via GlobeNewswire Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury July 10, 2023 New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI From Nexalin Technology, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.